A new study by investigators from Brigham and Women’s Hospital in a preclinical model demonstrates the potential for restoring fertility when the ovaries have stopped working.
Research directed by Johns Hopkins showed that for patients with operable pancreatic cancers, a three-pronged combination immunotherapy treatment—consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment—is safe, increases the amount of cancer-killing immune system T cells in the tumors, and appears effective when given two weeks prior to cancer-removal surgery. A description of the work was published in Nature Communications.
The dose escalation portion of the ongoing ANTLER phase I trial showed positive long-term follow-up clinical data for CB-010, an allogeneic anti-CD19 CAR-T cell therapy, in the treatment of relapsed or refractory B cell non-Hodgkin lymphoma.
Cedars-Sinai Cancer investigators found that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells.
Researchers from the Broad Institute of MIT and Harvard, the University of Georgia, and the One Health Company have published the results from the largest-ever genomic sequencing study of canine tumors. The study shows that dog and human cancers are far more genetically similar than previously known and underscores the important role of canine cancer data in accelerating the development of precision treatments for cancer patients of both species.
Surgeons who also conduct important biomedical research are struggling to obtain research funding, and that “broken pipeline” could spell extinction for surgeon-scientists and slow innovations for patients, a team of UVA Health experts said.
Results of a sub-study of the phase III CheckMate-901 trial showed that Opdivo (nivolumab) in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated statistically significant benefits in OS and PFS compared to standard-of-care cisplatin-based combinations as a first-line treatment for patients with unresectable or metastatic urothelial carcinoma who are eligible for cisplatin-based chemotherapy.
Positive high-level results from the TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.
A study shows that an artificial intelligence model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.
